^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Neo Vax (NEO-PV-01)

    i
    Other names: NEO-PV-01, NEO-PV 01, neoantigen-based personalized cancer vaccine
    Associations

    News

    Trials
    Company:
    BioNTech
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    4ms
    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=56, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Jun 2026 --> Feb 2027 | Trial primary completion date: Jun 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation
    |
    Keytruda (pembrolizumab) • temozolomide • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)
    7ms
    A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. (clinicaltrials.gov)
    P1, N=15, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Mar 2026 --> May 2027
    Trial primary completion date
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Neo Vax (NEO-PV-01)
    8ms
    Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Feb 2024 --> Dec 2026
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab) • Neo Vax (NEO-PV-01)
    9ms
    NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Jan 2027 --> Sep 2030 | Trial primary completion date: Jan 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Mobista (CDX-301) • Neo Vax (NEO-PV-01)
    1year
    Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Dana-Farber Cancer Institute | N=20 --> 11
    Enrollment change • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Neo Vax (NEO-PV-01)
    1year
    NeoVax Plus Ipilimumab in Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Patrick Ott, MD, PhD | Trial completion date: Sep 2026 --> May 2030
    Trial completion date
    |
    Yervoy (ipilimumab) • Neo Vax (NEO-PV-01)
    over1year
    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (clinicaltrials.gov)
    P1, N=56, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Keytruda (pembrolizumab) • temozolomide • Neo Vax (NEO-PV-01)
    over1year
    NeoVax With Nivolumab in Patients With Ovarian Cancer (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2024 --> Apr 2025
    Enrollment closed • Trial primary completion date
    |
    Opdivo (nivolumab) • Neo Vax (NEO-PV-01)
    over1year
    Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma. (PubMed, Clin Cancer Res)
    Collectively, our findings suggest NeoVax did stimulate expansion of neoantigen-specific effector T cells and provide encouraging results to aid in the development of future neoantigen vaccine-based clinical trials in patients with GBM. Herein, we demonstrate the feasibility of incorporating multisector sampling in cancer vaccine design and provide information on the clinical applicability of clonality, distribution, and immunogenicity of the neoantigen landscape in GBM patients.
    Journal
    |
    IFNG (Interferon, gamma)
    |
    Neo Vax (NEO-PV-01)
    over1year
    NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Dana-Farber Cancer Institute | N=20 --> 30
    Enrollment change • Combination therapy
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Mobista (CDX-301) • Neo Vax (NEO-PV-01)
    over1year
    Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Mar 2026 --> Dec 2033
    Trial completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab) • Neo Vax (NEO-PV-01)
    almost2years
    Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Neo Vax (NEO-PV-01)